X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (432) 432
cinacalcet hydrochloride (354) 354
index medicus (319) 319
male (258) 258
cinacalcet (255) 255
secondary hyperparathyroidism (254) 254
female (243) 243
naphthalenes - therapeutic use (235) 235
middle aged (217) 217
urology & nephrology (215) 215
hyperparathyroidism, secondary - drug therapy (211) 211
parathyroid hormone - blood (174) 174
hyperparathyroidism (172) 172
parathyroid hormone (164) 164
calcium - blood (142) 142
aged (140) 140
adult (136) 136
hyperparathyroidism, secondary - etiology (132) 132
calcium (127) 127
renal dialysis (120) 120
hemodialysis (119) 119
treatment outcome (116) 116
kidney failure, chronic - complications (115) 115
naphthalenes - administration & dosage (103) 103
hemodialysis-patients (99) 99
kidney failure, chronic - therapy (84) 84
vitamin d (82) 82
calcium-sensing receptor (81) 81
parathyroidectomy (81) 81
parathyroid-hormone (78) 78
chronic kidney-disease (77) 77
hyperparathyroidism, secondary - blood (76) 76
calcimimetic agents - therapeutic use (75) 75
dialysis (75) 75
phosphorus - blood (74) 74
calcimimetics (71) 71
nephrology (71) 71
naphthalenes - adverse effects (70) 70
naphthalenes - pharmacology (66) 66
pharmacology & pharmacy (62) 62
mineral metabolism (61) 61
mortality (61) 61
medicine & public health (60) 60
transplantation (59) 59
animals (58) 58
care and treatment (58) 58
disease (58) 58
dialysis patients (57) 57
vitamin-d (55) 55
chronic kidney disease (54) 54
endocrinology & metabolism (54) 54
hyperparathyroidism - drug therapy (54) 54
renal dialysis - adverse effects (54) 54
cinacalcet hydrochloride - therapeutic use (50) 50
kidney diseases (50) 50
drug therapy (49) 49
hypercalcemia (49) 49
stage renal-disease (49) 49
hcl (48) 48
vitamin d - therapeutic use (48) 48
phosphorus (47) 47
prospective studies (47) 47
calcimimetic (46) 46
cardiovascular-disease (46) 46
chronic kidney failure (45) 45
dose-response relationship, drug (45) 45
calcification (43) 43
drug therapy, combination (43) 43
time factors (43) 43
calcium - metabolism (42) 42
dosage and administration (40) 40
hypercalcemia - drug therapy (39) 39
rats (39) 39
surgery (39) 39
vascular calcification (39) 39
aged, 80 and over (37) 37
calcimimetic agents - administration & dosage (37) 37
therapy (36) 36
health aspects (35) 35
internal medicine (35) 35
kidney transplantation (35) 35
analysis (34) 34
cinacalcet hcl (34) 34
calcitriol (33) 33
drug administration schedule (33) 33
physiological aspects (33) 33
research (33) 33
retrospective studies (33) 33
risk factors (33) 33
vitamin d - administration & dosage (33) 33
hematology (32) 32
hypercalcemia - etiology (32) 32
renal insufficiency, chronic - complications (32) 32
calcimimetic amg-073 (31) 31
parathyroid-hormone levels (31) 31
kidneys (30) 30
metabolism (30) 30
primary hyperparathyroidism (30) 30
hyperparathyroidism, primary - drug therapy (29) 29
parathyroid (29) 29
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (496) 496
Japanese (8) 8
Polish (6) 6
Spanish (4) 4
Danish (3) 3
German (2) 2
Chinese (1) 1
French (1) 1
Italian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 2, pp. 156 - 164
IMPORTANCE: Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause and cardiovascular mortality. Control is... 
MEDICINE, GENERAL & INTERNAL | CALCIUM-SENSING RECEPTOR | PEPTIDE AGONIST | EVOLVE TRIAL | CARDIOVASCULAR-DISEASE | MINERAL METABOLISM | BONE | CHRONIC KIDNEY-DISEASE | AMG 416 VELCALCETIDE | FGF23 | DIALYSIS | Calcimimetic Agents - administration & dosage | Nausea - chemically induced | Cinacalcet Hydrochloride - pharmacology | Humans | Middle Aged | Calcium - administration & dosage | Male | Cinacalcet Hydrochloride - administration & dosage | Parathyroid Hormone - blood | Peptides - administration & dosage | Calcium - blood | Time Factors | Calcimimetic Agents - pharmacology | Cinacalcet Hydrochloride - adverse effects | Female | Double-Blind Method | Hyperparathyroidism, Secondary - drug therapy | Administration, Oral | Biomarkers - blood | Calcimimetic Agents - adverse effects | Peptides - pharmacology | Kidney Failure, Chronic - therapy | Hyperparathyroidism, Secondary - blood | Vomiting - chemically induced | Fibroblast Growth Factors - blood | Kidney Failure, Chronic - complications | Infusions, Intravenous | Hyperparathyroidism, Secondary - etiology | Peptides - adverse effects | Renal Dialysis | Complications and side effects | Usage | Care and treatment | Parathyroid hormone | Hemodialysis | Dosage and administration | Research | Cinacalcet | Hyperparathyroidism | Patient safety | Endocrine system | Hyperthyroidism | Clinical outcomes
Journal Article
Journal Article
Journal Article
Therapeutic Apheresis and Dialysis, ISSN 1744-9979, 08/2015, Volume 19, Issue 4, pp. 367 - 377
Journal Article
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 07/2015, Volume 24, Issue 7, pp. 738 - 747
Journal Article
Journal Article
Endocrine, ISSN 1355-008X, 5/2015, Volume 49, Issue 1, pp. 267 - 273
Journal Article
Journal Article